KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Convertible Debt: 2009-2011

Historic Convertible Debt for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Dec 2011 value amounting to $531.0 million.

  • Teva Pharmaceutical Industries' Convertible Debt was N/A to $1.3 billion in Q1 2015 from the same period last year, while for Mar 2015 it was $1.3 billion, marking a year-over-year change of. This contributed to the annual value of $531.0 million for FY2011, which is 3984.62% up from last year.
  • Teva Pharmaceutical Industries' Convertible Debt amounted to $531.0 million in FY2011, which was up 3,984.62% from $13.0 million recorded in FY2010.
  • Teva Pharmaceutical Industries' Convertible Debt's 5-year high stood at $817.0 million during FY2009, with a 5-year trough of $13.0 million in FY2010.
  • Its 3-year average for Convertible Debt is $453.7 million, with a median of $531.0 million in 2011.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Convertible Debt plummeted by 98.41% in 2010, and later spiked by 3,984.62% in 2011.
  • Teva Pharmaceutical Industries' Convertible Debt (Yearly) stood at $817.0 million in 2009, then slumped by 98.41% to $13.0 million in 2010, then soared by 3,984.62% to $531.0 million in 2011.